PENTAX Medical Appoints Dr. Hudson Garrett, Global Chief Clinical Officer
PENTAX Medical, a division of HOYA Corporation, announced the appointment of Dr. Hudson Garrett to the position of Global Chief Clinical Officer. In this executive role, Hudson Garrett is responsible for leading all PENTAX Medical clinical related activities globally.
PENTAX Medical has decided to establish this role to accelerate its focus on delivering clinically relevant products to improve quality and standard of patient care. Dr. Garrett’s expertise and experiences in infection control in various medical institutions will enforce its commitment to minimize risk of infection and cross contamination. It will also further develop the scientific community by investing in professional education to raise the bar of patient care.
“Hudson joins PENTAX Medical with valuable expertise gained from various segments of the medical field on the vender and provider side”, said David Woods, Global CMO of PENTAX Medical, HOYA Group. “He has the credentials and expertise to oversee PENTAX Medical’s clinical activities by working with our customers, industry partners and internal team members to develop and deliver high quality products cost effectively with attention to provider and patient satisfaction.”
“I am committed to make the best use of my clinical background in infection prevention, control and clinical affairs to position PENTAX Medical as a thought leader in medical device hygiene, evidence-based clinical education, and clinical research”, Dr. Garrett says. “I am committed to ensuring we clearly demonstrate the PENTAX Medical ethos of offering clinically advanced evidence-based products.”
Dr. Garrett holds a Bachelor of Science degree in biology/chemistry and nursing, dual masters in nursing and public health, a post-masters certificate as a family nurse practitioner, a post-masters certificate in infection prevention and control, and a PhD in healthcare administration and policy. He is a graduate of the Johns Hopkins Fellowship in Infection Control and Hospital Epidemiology, and was honored as a Who’s Who in Infection Control Today Magazine in 2013.
About PENTAX Medical
PENTAX Medical is a division of Hoya Group. Its mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. Through leading edge R&D and manufacturing, PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community. Headquartered in Japan, PENTAX Medical has a worldwide focus and presence with R&D, regional sales, service, and in-country facilities around the globe. For more information, please visit: www.pentaxmedical.com .
GM, Corporate Communications & Product Branding
Mobile phone: +81-80-4794-5842
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PIERRE-FABRE23.6.2018 13:02 | pressemeddelelse
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress
SERVIER23.6.2018 10:12 | pressemeddelelse
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho
SOFTOMOTIVE22.6.2018 17:15 | pressemeddelelse
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA
TX-ASCEND-PERFORMANCE22.6.2018 16:02 | pressemeddelelse
Ascend Performance Materials Announces Price Increase for Intermediate Materials
DELTICOM-AG/MOTO-TYRES.C22.6.2018 15:43 | pressemeddelelse
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk
BOEHRINGER-INGELHEIM22.6.2018 14:02 | pressemeddelelse
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum